80 likes | 287 Views
The Lilly MDR-TB Partnership. Increasing Corporate Engagement on Tuberculosis Metropolitan Auditorium, Cape Town, 23.02.2010. Creating a sustainable strategy for combating a global public health pandemic. 360° Approach: Partnership Overview. Since 2003, Lilly has lead a comprehensive approach
E N D
The Lilly MDR-TB Partnership Increasing Corporate Engagement on Tuberculosis Metropolitan Auditorium, Cape Town, 23.02.2010 Creating a sustainable strategy for combating a global public health pandemic
360° Approach: Partnership Overview Since 2003, Lilly has lead a comprehensive approach to fighting MDR-TB through Awareness and Prevention Community Support and Patient Advocacy Treatment, Training and Surveillance Research Transferring Technology Reaching patients throughout the world
International Organizations and NGOs International Federation of Red Cross & Red Crescent Societies World Health Organization Foundation for Professional Development Centers for Disease Control World Economic Forum Global Business Coalition UNICEF USAID Government Departments Department of Health Department of Public Service and Administration Healthcare Provider Networks International Hospital Federation International Council of Nurses - DENOSA World Medical Association - SAMA Manufacturing Partners Aspen Pharmacare (South Africa) Hisun (China) Shasun (India) SIA/Biocom (Russia) The Partners
World Economic Forum/GBC Develop a Global Awareness Toolkit for Tuberculosis/MDR-TB in the workplace and disseminate through WEF/GBC member companies Provide educational material targeting employees and in-plant healthcare staff Pilot tested in India and adapt for other high-burden countries with large business communities Conducted 3 workshops in South Africa in 2009 reaching over 60 participants from 33 companies Workplace Toolkit
Share Lilly’s specific and general manufacturing knowledge Create self-sustaining centers of manufacturing excellence capable of providing additional products and employment Support reliable generic producers to ensure expanded multi-source availability of the two drugs Offer manufacturing firms in MDR-TB “hot spots” the technology to produce capreomycin and cycloserine Give training in GMPs and Good Business Practices Provide 10 full-time Lilly staff on-site over 4 years for technical assistance/training Facilities in China and India receive technology to produce capreomycin and cycloserine API’s respectively, and South Africa and Russia produce both products Transferring of Technology
Technology successfully transferred to “hot spot” producers
Thank You! Dr Osborn Mahanjana Corporate Affairs Director Lilly MDR-TB Partnership mahanjanaos@lilly.com South Africa www.lilly.com www.lillymdr-tb.com